Dr Adrien Saliou obtained his Engineer degree in Biotechnology in 2009 from the University of Strasbourg (“Ecole Supérieure de Biotechnologie de Strasbourg”, ESBS, France). He first took a scientist position at Harvard Medical School (Boston, MA, USA) and worked in the microbiology field where he studied the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system (2009). In 2013, he defended his PhD in the field of virology at the University of Toulouse III (Toulouse, France). During this period, he investigated the resistance mechanisms of HIV-1 to CCR5 antagonists. He notably developed and implemented the next-generation sequencing in clinical routine to better characterize the HIV-1 quasispecies and to detect minor HIV-1 variants. In 2013, Dr. Adrien Saliou joined the Institut Curie (Paris, France), in the translational research department as a Post-doctoral fellow, in order to study circulating biomarkers in cancer patients. He developed the concept of liquid biopsy at the laboratory and the circulating tumor DNA analysis using next-generation sequencing and droplet digital PCR. In 2015, he joined BIOASTER, the recently created French Technology Research Institute for Microbiology and Infectious Diseases, as senior researcher in the Genomics and Transcriptomics Unit. He develops and implements molecular analysis with the next-generation sequencing, PCR and microarray platforms, in various collaborative projects. Dr Adrien Saliou has an expertise in the areas such as genomic sequencing, metagenomics, genotyping, transcriptomics and single-cell sequencing. He has published numerous well cited international peer-reviewed journals and conference articles.
Microbiology, virology, cancerology, infectious diseases, bioinformatics, next-generation sequencing, molecular barcoding, microfluidics, host-pathogen interaction, microbiota